ACE2 and chronic kidney disease: For example, increased ACE2 activity predicted adverse CV outcomes in heart failure,[16] but not in patients after emergency orthopedic surgery[17] or with chronic kidney disease.[13, 14] These differences may reflect the patient population, the relative cardiovascular risk of the patient population or the length of follow up.